Keryx Biopharmaceuticals Given New $19.00 Price Target at Stifel Nicolaus
The firm currently has a "buy" rating on the stock. Stifel Nicolaus' price target points to a potential upside of 25.74% from the company's current price.
Keryx Biopharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript
Greetings and welcome to the Keryx Biopharmaceuticals Investor Conference Call. At this time, all participants are in a listen-only mode.
Keryx Biopharmaceuticals (KERX) Announces Quarterly Earnings, Misses Estimates By $0.05 EPS
Keryx Biopharmaceuticals released its earnings data on Wednesday. The company reported earnings per share for the quarter, missing the consensus estimate of by $0.05, American Banking & Market News reports.
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth...
Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Thursday, March 13, 2014 at 8:30 a.m. EDT to discuss results for the fourth quarter and year ended December ... (more)
Keryx announces submission of MAA for Zerenex to EMA
Keryx announces submission of MAA for Zerenex to EMA Keryx Biopharmaceuticals announced it has submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, seeking the approval of Zerenex as a treatment for hyperphosphatemia in patients with chronic kidney disease, or CKD, including dialysis- and non-dialysis ... (more)
Keryx Biopharmaceuticals Sees Significant Growth in Short Interest
Keryx Biopharmaceuticals was the target of a significant growth in short interest during the month of January.
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
NEW YORK, Feb. 26, 2014 -- Keryx Biopharmaceuticals, Inc. today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following upcoming healthcare investor conferences: Live audio webcasts of these presentations will be accessible within the Investor Relations section of the Company's Website at ... (more)
Ferric Citrate [Zerenex] For The Treatment Of Hyperphosphatemia: A New Use For An Old Compound
Ferric citrate is being developed as a phosphate binder by Keryx Biopharmaceuticals for the treatment of hyperphosphatemia in patients with chronic kidney disease [CDK] on dialysis, with a PDUFA date of June 7, 2014.
Keryx Biopharmaceuticals Announces The Appointment Of As Vice President Of Marketing
Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced the appointment of Abraham Ceesay as Vice President of Marketing and Operations.